Reprogramming Synthetic Cells for Targeted Cancer Therapy

Boon Huat Lim, Yutong Yin, Hua Ye, Zhanfeng Cui, Antonis Papachristodoulou, Wei E. HuangACS 2022 · DOI

TL;DR

This paper presents a novel approach to cancer therapy using engineered, chromosome-free synthetic cells (SimCells and mini-SimCells) that can specifically target cancer cells and induce cell death. These synthetic cells offer a safer alternative to traditional engineered bacteria by eliminating the risk of uncontrolled growth and genetic instability, paving the way for more precise and effective cancer treatments.

What Problem Does This Paper Address?

Traditional approaches to bacterial cancer therapy involve engineering live bacteria to target tumors and deliver therapeutic agents. While promising, these methods face significant hurdles for clinical translation, primarily due to concerns about genetic instability and the potential for uncontrolled bacterial replication within the patient. This poses safety risks and can lead to unpredictable therapeutic outcomes. Furthermore, achieving precise targeting of cancer cells can be challenging, as bacterial colonization in tumors doesn't always translate effectively across different hosts. This paper addresses these limitations by developing "safe and live drugs" in the form of chromosome-free synthetic cells (SimCells and mini-SimCells) that are designed for targeted cancer cell binding and destruction, while mitigating the risks associated with live, replicating bacteria.

Methods

The researchers engineered E. coli BL21(DE3) to display nanobodies on their surface, enabling specific binding to cancer cells. They utilized a surface display system based on the $\beta$-intimin domain for efficient nanobody presentation. Two plasmid systems, pNV_2 (low expression) and pNV_3 (high expression), were designed to control nanobody expression levels. For targeted therapy, they engineered SimCells and mini-SimCells, which are chromosome-free bacterial derivatives. SimCells were generated using an I-CeuI endonuclease-induced system, leading to chromosome degradation, while mini-SimCells were produced by knocking out the minD gene, resulting in minicell formation. These synthetic cells were further engineered with an anti-CEA (carcinoembryonic antigen) nanobody to target colorectal cancer cells. To enhance their therapeutic potential, an inducible gene circuit was incorporated, allowing the conversion of salicylate into catechol, a potent anticancer compound.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Safety through Chromosome-Free Design: The development of SimCells and mini-SimCells, which are chromosome-free and non-replicating, directly addresses the safety concerns associated with live bacterial therapies. This eliminates the risk of uncontrolled growth and genetic instability.
  • Modular Targeting with Nanobodies: The use of nanobodies displayed on the bacterial surface provides a highly specific and modular targeting mechanism. This allows for easy adaptation to different cancer biomarkers by simply changing the nanobody.
  • Dual-Action Therapy: The engineered SimCells and mini-SimCells not only bind to cancer cells but also induce cell death through membrane compromise. This "built-in" cytotoxic effect offers a direct therapeutic mechanism.
  • Inducible Anticancer Payload: The integration of an inducible gene circuit for catechol production demonstrates the potential for these synthetic cells to act as drug delivery vehicles, further enhancing their therapeutic efficacy in a controlled manner.
  • Mimicking Diagnostic Assays: The use of a biological agglutination test to confirm nanobody binding to CEA mirrors clinically used diagnostic methods, suggesting potential for future diagnostic applications.

Key Results

  • Engineered E. coli strains expressing anti-CEA nanobodies (C17 and C43) specifically bound to CEA-expressing Caco2 cancer cells in vitro, while showing no binding to non-CEA-expressing SW480 cells.
  • Mini-SimCells and SimCells engineered with anti-CEA nanobodies also demonstrated specific binding to Caco2 cells.
  • Targeted mini-SimCells and SimCells induced significant cytotoxicity in Caco2 cells, leading to cell death by compromising the plasma membrane. Cytotoxicity was observed as early as 8 hours post-incubation and increased over time.
  • The addition of salicylic acid, which was converted to catechol by the engineered SimCells, further enhanced the cancer-killing effect, demonstrating the potential of the inducible gene circuit.

Limitations and Future Work

The authors acknowledge that the observed cytotoxicity from direct binding alone was relatively low, suggesting that further improvements are necessary for clinical relevance. They also note that microscopic imaging was conducted under less-than-ideal conditions, which may have affected the observed timescale of cell killing.

Future work could focus on:

  • Optimizing the cytotoxic mechanisms of the SimCells and mini-SimCells to achieve higher killing efficiency.
  • Developing more sophisticated inducible gene circuits for the controlled release of a wider range of therapeutic payloads.
  • Conducting in vivo studies to evaluate the efficacy, safety, and biodistribution of these engineered synthetic cells in animal models.
  • Exploring the use of SimCells and mini-SimCells for targeting other cancer types by engineering them with nanobodies against different cancer biomarkers.
  • Investigating the potential for these synthetic cells to elicit an anti-tumor immune response.

Summary updated

Abstract

Advances in synthetic biology enable the reprogramming of bacteria as smart agents to specifically target tumors and locally release anticancer drugs in a highly controlled manner. However, the bench-to-bedside translation of engineered bacteria is often impeded by genetic instability and the potential risk of uncontrollable replication of engineered bacteria inside the patient. SimCells (simple cells) are chromosome-free bacteria controlled by designed gene circuits, which can bypass the interference of the native gene network in bacteria and eliminate the risk of bacterial uncontrolled growth. Here, we describe the reprogramming of SimCells and mini-SimCells to serve as "safe and live drugs" for targeted cancer therapy. We engineer SimCells to display nanobodies on the surface for the binding of carcinoembryonic antigen (CEA), which is an important biomarker found commonly in colorectal cancer cells. We show that SimCells and mini-SimCells with surface display of anti-CEA nanobody can specifically bind CEA-expressing Caco2 cancer cells <i>in vitro</i> while leaving the non-CEA-expressing SW80 cancer cells untouched. These cancer-targeting SimCells and mini-SimCells induced cancer cell death <i>in vitro</i> by compromising the plasma membrane of cancer cells. The cancer-killing effect can be further enhanced by an aspirin/salicylate inducible gene circuit that converts salicylate into catechol, a potent anticancer. This work highlights the potential of SimCells and mini-SimCells for targeted cancer therapy and lays the foundation for the application of synthetic biology to medicine.
BibTeX
@inproceedings{lim2022reprogramming,
  author = {Boon Huat Lim and Yutong Yin and Hua Ye and Zhanfeng Cui and Antonis Papachristodoulou and Wei E. Huang},
  title = {{Reprogramming Synthetic Cells for Targeted Cancer Therapy}},
  booktitle = {ACS},
  year = {2022},
  doi = {10.1021/acssynbio.1c00631},
}
Figure